Analysis of pharmaceutical products with large price changes in a regional hospital system

Christina M.L. Kelton, Robert P. Rebelein, Michelle L. Dusing, Yann Ferrand, Jeff J. Guo

Research output: Contribution to journalArticle

Abstract

Purpose: Large price swings for individual drugs complicate the hospital purchasing process, both increasing costs and adversely affecting patient treatment therapy. The objectives for this study are, for a large regional hospital buyer, to describe price changes for individual drugs, therapeutic classes, and drug companies, and to determine factors associated with large price swings. Methods: We constructed monthly transaction prices for over 5,000 individual drug products purchased by the Buyer during 2000 and 2001. Of those, we were able to determine annual price changes for 3,085 products, which we describe in detail. The 319 products with annual price swings of 20 percent or more between 2000 and 2001 were selected for further analysis. Percentage change in price was regressed on patent expiration (whether a patent expired during the time period), drug shortage (whether one occurred during the time period), whether the drug was branded or generic, and Buyer expenditure on the drug over the study period. Results: Out of those companies and therapeutic classes, respectively, which accounted for over $1 million in expenditures for the Buyer over 2000-2001, GlaxoSmithKline and sympathomimetics exhibited the highest upswings, while TAP Pharmaceuticals and quinolones were responsible for the largest downswings. Regression results revealed that drug shortages beginning in 2000 (t = 2.25, p 0.05) and 2001 (t = 3.91, p 0.01) were statistically associated with large upward price swings; large downswings were observed for generic drugs whose branded counterpart had a patent expiration in either 1999 (t = -2.88, p 0.01) or 2000 (t = -1.66, p 0.10). Price swings were significantly smaller for heavily purchased drugs (t = -2.74, p 0.01). Conclusion: Underlying the overall drug price inflation rate are many different individual price changes. Upswings are associated with drug shortages, while downswings are caused in part by patent expiration. Generally, with some notable exceptions, high-budget items are not characterized by the largest swings.

Original languageEnglish (US)
Pages (from-to)61-86
Number of pages26
JournalJournal of Pharmaceutical Finance, Economics and Policy
Volume16
Issue number2
DOIs
StatePublished - Jan 30 2008
Externally publishedYes

Fingerprint

Pharmaceutical Preparations
Health Expenditures
Hospital Purchasings
Generic Drugs
Sympathomimetics
Quinolones
Economic Inflation
Budgets
Therapeutics
Costs and Cost Analysis

Keywords

  • Hospital drug purchasing
  • Hospital drug shortages
  • Price stickiness

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Health Policy

Cite this

Analysis of pharmaceutical products with large price changes in a regional hospital system. / Kelton, Christina M.L.; Rebelein, Robert P.; Dusing, Michelle L.; Ferrand, Yann; Guo, Jeff J.

In: Journal of Pharmaceutical Finance, Economics and Policy, Vol. 16, No. 2, 30.01.2008, p. 61-86.

Research output: Contribution to journalArticle

Kelton, Christina M.L. ; Rebelein, Robert P. ; Dusing, Michelle L. ; Ferrand, Yann ; Guo, Jeff J. / Analysis of pharmaceutical products with large price changes in a regional hospital system. In: Journal of Pharmaceutical Finance, Economics and Policy. 2008 ; Vol. 16, No. 2. pp. 61-86.
@article{1e67d2beaf5640f7818baba103d4d3ff,
title = "Analysis of pharmaceutical products with large price changes in a regional hospital system",
abstract = "Purpose: Large price swings for individual drugs complicate the hospital purchasing process, both increasing costs and adversely affecting patient treatment therapy. The objectives for this study are, for a large regional hospital buyer, to describe price changes for individual drugs, therapeutic classes, and drug companies, and to determine factors associated with large price swings. Methods: We constructed monthly transaction prices for over 5,000 individual drug products purchased by the Buyer during 2000 and 2001. Of those, we were able to determine annual price changes for 3,085 products, which we describe in detail. The 319 products with annual price swings of 20 percent or more between 2000 and 2001 were selected for further analysis. Percentage change in price was regressed on patent expiration (whether a patent expired during the time period), drug shortage (whether one occurred during the time period), whether the drug was branded or generic, and Buyer expenditure on the drug over the study period. Results: Out of those companies and therapeutic classes, respectively, which accounted for over $1 million in expenditures for the Buyer over 2000-2001, GlaxoSmithKline and sympathomimetics exhibited the highest upswings, while TAP Pharmaceuticals and quinolones were responsible for the largest downswings. Regression results revealed that drug shortages beginning in 2000 (t = 2.25, p 0.05) and 2001 (t = 3.91, p 0.01) were statistically associated with large upward price swings; large downswings were observed for generic drugs whose branded counterpart had a patent expiration in either 1999 (t = -2.88, p 0.01) or 2000 (t = -1.66, p 0.10). Price swings were significantly smaller for heavily purchased drugs (t = -2.74, p 0.01). Conclusion: Underlying the overall drug price inflation rate are many different individual price changes. Upswings are associated with drug shortages, while downswings are caused in part by patent expiration. Generally, with some notable exceptions, high-budget items are not characterized by the largest swings.",
keywords = "Hospital drug purchasing, Hospital drug shortages, Price stickiness",
author = "Kelton, {Christina M.L.} and Rebelein, {Robert P.} and Dusing, {Michelle L.} and Yann Ferrand and Guo, {Jeff J.}",
year = "2008",
month = "1",
day = "30",
doi = "10.1300/J371v16n02-05",
language = "English (US)",
volume = "16",
pages = "61--86",
journal = "Journal of Pharmaceutical Finance, Economics and Policy",
issn = "1538-5698",
publisher = "Haworth Press Inc.",
number = "2",

}

TY - JOUR

T1 - Analysis of pharmaceutical products with large price changes in a regional hospital system

AU - Kelton, Christina M.L.

AU - Rebelein, Robert P.

AU - Dusing, Michelle L.

AU - Ferrand, Yann

AU - Guo, Jeff J.

PY - 2008/1/30

Y1 - 2008/1/30

N2 - Purpose: Large price swings for individual drugs complicate the hospital purchasing process, both increasing costs and adversely affecting patient treatment therapy. The objectives for this study are, for a large regional hospital buyer, to describe price changes for individual drugs, therapeutic classes, and drug companies, and to determine factors associated with large price swings. Methods: We constructed monthly transaction prices for over 5,000 individual drug products purchased by the Buyer during 2000 and 2001. Of those, we were able to determine annual price changes for 3,085 products, which we describe in detail. The 319 products with annual price swings of 20 percent or more between 2000 and 2001 were selected for further analysis. Percentage change in price was regressed on patent expiration (whether a patent expired during the time period), drug shortage (whether one occurred during the time period), whether the drug was branded or generic, and Buyer expenditure on the drug over the study period. Results: Out of those companies and therapeutic classes, respectively, which accounted for over $1 million in expenditures for the Buyer over 2000-2001, GlaxoSmithKline and sympathomimetics exhibited the highest upswings, while TAP Pharmaceuticals and quinolones were responsible for the largest downswings. Regression results revealed that drug shortages beginning in 2000 (t = 2.25, p 0.05) and 2001 (t = 3.91, p 0.01) were statistically associated with large upward price swings; large downswings were observed for generic drugs whose branded counterpart had a patent expiration in either 1999 (t = -2.88, p 0.01) or 2000 (t = -1.66, p 0.10). Price swings were significantly smaller for heavily purchased drugs (t = -2.74, p 0.01). Conclusion: Underlying the overall drug price inflation rate are many different individual price changes. Upswings are associated with drug shortages, while downswings are caused in part by patent expiration. Generally, with some notable exceptions, high-budget items are not characterized by the largest swings.

AB - Purpose: Large price swings for individual drugs complicate the hospital purchasing process, both increasing costs and adversely affecting patient treatment therapy. The objectives for this study are, for a large regional hospital buyer, to describe price changes for individual drugs, therapeutic classes, and drug companies, and to determine factors associated with large price swings. Methods: We constructed monthly transaction prices for over 5,000 individual drug products purchased by the Buyer during 2000 and 2001. Of those, we were able to determine annual price changes for 3,085 products, which we describe in detail. The 319 products with annual price swings of 20 percent or more between 2000 and 2001 were selected for further analysis. Percentage change in price was regressed on patent expiration (whether a patent expired during the time period), drug shortage (whether one occurred during the time period), whether the drug was branded or generic, and Buyer expenditure on the drug over the study period. Results: Out of those companies and therapeutic classes, respectively, which accounted for over $1 million in expenditures for the Buyer over 2000-2001, GlaxoSmithKline and sympathomimetics exhibited the highest upswings, while TAP Pharmaceuticals and quinolones were responsible for the largest downswings. Regression results revealed that drug shortages beginning in 2000 (t = 2.25, p 0.05) and 2001 (t = 3.91, p 0.01) were statistically associated with large upward price swings; large downswings were observed for generic drugs whose branded counterpart had a patent expiration in either 1999 (t = -2.88, p 0.01) or 2000 (t = -1.66, p 0.10). Price swings were significantly smaller for heavily purchased drugs (t = -2.74, p 0.01). Conclusion: Underlying the overall drug price inflation rate are many different individual price changes. Upswings are associated with drug shortages, while downswings are caused in part by patent expiration. Generally, with some notable exceptions, high-budget items are not characterized by the largest swings.

KW - Hospital drug purchasing

KW - Hospital drug shortages

KW - Price stickiness

UR - http://www.scopus.com/inward/record.url?scp=67650617224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650617224&partnerID=8YFLogxK

U2 - 10.1300/J371v16n02-05

DO - 10.1300/J371v16n02-05

M3 - Article

AN - SCOPUS:67650617224

VL - 16

SP - 61

EP - 86

JO - Journal of Pharmaceutical Finance, Economics and Policy

JF - Journal of Pharmaceutical Finance, Economics and Policy

SN - 1538-5698

IS - 2

ER -